Invention Grant
- Patent Title: Use of inhibitors of the activity or function of PI3K
-
Application No.: US14365512Application Date: 2012-12-14
-
Publication No.: US09949979B2Publication Date: 2018-04-24
- Inventor: Nigel Graham Cooke , Paulo Antonio Fernandes Gomes Dos Santos , Pascal Furet , Christina Hebach , Klemens Hoegenauer , Gregory Hollingworth , Christoph Kalis , Ian Lewis , Alexander Baxter Smith , Nicolas Soldermann , Frederic Stauffer , Ross Strang , Frank Stowasser , Nicola Tuffilli , Anette Von Matt , Romain Wolf , Frederic Zecri
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent David Kurlandsky
- International Application: PCT/IB2012/057332 WO 20121214
- International Announcement: WO2013/088404 WO 20130620
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/5377 ; A61K31/541 ; A61K31/517 ; A61K31/551 ; C07D401/14 ; C07D413/14 ; C07D401/04 ; C07D403/04 ; C07D239/74 ; C07D487/08
Abstract:
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
Public/Granted literature
- US20150342951A1 Use of Inhibitors of the Activity or Function of PI3K Public/Granted day:2015-12-03
Information query
IPC分类:
